Al-Lamki RS, Sadler TJ, Wang J, Reid MJ, Warren AY, Movassagh M, Lu W, Mills IG, Neal DE, Burge J, Vandenebeele P, Pober JS, Bradley JR.
Tumor necrosis factor receptor expression and signaling in renal cell carcinoma.
Am J Pathol 2010;177(2):943-54.
Collin SM, Metcalfe C, Refsum H, Lewis SJ, Zuccolo L, Smith GD, Chen L, Harris R, Davis M, Marsden G, Johnston C, Lane JA, Ebbing M, Ueland PM, Grau MV, Baron JA, Donovan JL, Neal DE, Hamdy FC, Smith AD, Martin RM.
Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis.
Cancer Epidemiol Biomarkers Prev 2010;19(6):1632-42.
Elliott KS, Zeggini E, McCarthy MI et al.
Evaluation of association of HNF1B variants with diverse cancers: collaborative analysis of data from 19 genome-wide association studies.
PLoS One 2010;5(5):e10858.
Hayami S, Yoshimatsu M, Veerakumarasivam A, Unoki M, Iwai Y, Tsunoda T, Field HI, Kelly JD, Neal DE, Yamaue H, Ponder BA, Nakamura Y, Hamamoto R.
Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway.
Mol Cancer 2010;9:59.
Hori S, Jabbar T, Kachroo N, Vasconcelos JC, Robson CN, Gnanapragasam VJ.
Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer.
J Cancer Res Clin Oncol 2011;137(2):235.
Lyratzopoulos G, Barbiere JM, Greenberg DC, Wright KA, Neal DE.
Population based time trends and socioeconomic variation in use of radiotherapy and radical surgery for prostate cancer in a UK region: continuous survey.
BMJ 2010;340:c1928.
Macefield RC, Metcalfe C, Lane JA, Donovan JL, Avery KN, Blazeby JM, Down L, Neal DE, Hamdy FC, Vedhara K, ProtecT Study Group.
Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result.
Br J Cancer 2010;102(9):1335-40.
Top
Murphy T, Darby S, Mathers ME, Gnanapragasam VJ.
Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype.
J Pathol 2010 Mar;220(4):452-60.
Neal DE.
PSA testing for prostate cancer improves survival - but can we do better?
Lancet Oncol 2010;11(8):702-3.
Tilling K, Garmo H, Metcalfe C, Holmberg L, Hamdy FC, Neal DE, Adolfsson J, Martin RM, Davis M, Fall K, Lane JA, Adami HO, Bill-Axelson A, Johansson JE, Donovan JLDevelopment of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts.
Eur Urol 2010;57(3):446-52.
Whitaker HC, Warren AY, Eeles R, Kote-Jarai Z, Neal DE.
The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target.
Prostate 2010;70(3):333-40.
Willems SH, Tape CJ, Stanley PL, Taylor NA, Mills IG, Neal DE, McCafferty J, Murphy G.
Thiol isomerases negatively regulate the cellular shedding activity of ADAM17.
Biochem J 2010;428(3):439-50.
